Share This Author
Prognostic value of F-18-FDG PET/CT in a large cohort of 495 patients with advanced neuroendocrine neoplasms (NEN) treated with peptide receptor radionuclide therapy (PRRT)
Combined PRLT using Ac-225 and Lu-177 labeled PSMA-617 (TANDEM-PRLT) in end-stage metastatic prostate cancer: a concept to reduce salivary gland toxicity?
First-in-human study of a novel somatostatin receptor antagonist Ga-68-NODAGA-LM3 for PET imaging in paraganglioma patients
Pregnancy and delivery after PRRT without sequelae
Long-term Nephrotoxicity After PRRT: Mythos or Reality?
Lu-177-PSMA-617 radioligand therapy in mCRPC patients with a single functioning kidney
Peptide Receptor Radionuclide Therapy (PRRT) in Patients with Grade 3 Neuroendocrine Neoplasms (NEN)
Effective Trade-off between Response and Toxicity by Using a Combination of Ac-225 and Lu-177 Labelled PSMA-617 for Progressive End-Stage Metastatic Prostate Cancer